Saturday 17 October 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
4.43
0.25
−5.34%
Follow MDXG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
96.25 | 18.81 | 20.52 | 24.93 |
+8 more quarters Free account |
P/S ratio |
1.60 | 1.51 | 2.39 | 2.63 | |
P/FCF ratio |
12.81 | 8.46 | 13.71 | 15.47 | |
P/Operating CF |
(56.82) | 312.06 | 40.09 | 35.23 | |
P/B ratio |
2.63 | 2.41 | 3.90 | 4.32 | |
Price to Tangible BV |
3.08 | 2.79 | 4.49 | 4.96 | |
EV/Sales |
1.27 | 1.14 | 2.04 | 2.31 | |
EV/EBITDA |
22.07 | 8.40 | 10.82 | 13.27 | |
EV/Operating CF |
9.76 | 6.29 | 11.52 | 13.41 | |
EV/FCF |
10.14 | 6.41 | 11.68 | 13.61 | |
Quick Ratio |
4.60 | 4.62 | 3.76 | 3.82 | |
Current Ratio |
5.33 | 5.39 | 4.32 | 4.41 | |
Net Debt/EBITDA |
7.01 | 9.85 | (6.10) | (4.51) | |
Debt/Assets |
6.12% | 5.70% | 5.24% | 5.71% | |
Debt/Equity |
0.08 | 0.07 | 0.07 | 0.08 | |
Asset Turnover |
1.24 | 1.34 | 1.38 | 1.40 | |
Operating CF/Net income |
0.67 | (0.17) | 1.64 | 1.75 | |
Capex/Depreciation |
(0.41) | (0.40) | (0.08) | (0.04) | |
Research and Development Expense of Revenue |
4.31% | 7.02% | 4.03% | 3.26% | |
Selling, General and Administrative Expense of Revenue |
92.88% | 90.24% | 61.88% | 60.67% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.10 | 0.10 | |
Share Based Compensation of Revenue |
1.40% | (2.88%) | 2.09% | 4.33% | |
Graham Net Nets |
0.25 | 0.30 | 0.19 | 0.17 | |
Graham Number |
1.15 | 2.78 | 3.59 | 3.19 | |
Earnings Yield |
1.04% | 5.32% | 4.87% | 4.01% | |
Free Cash Flow Yield |
7.81% | 11.82% | 7.29% | 6.47% | |
Revenue per Share |
0.44 | 0.40 | 0.80 | 0.77 | |
Operating CF per Share |
(0.07) | 0.01 | 0.17 | 0.20 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | 0.01 | 0.17 | 0.20 | |
Cash per Share |
0.92 | 1.08 | 1.12 | 0.96 | |
Shareholders Equity per Share |
1.46 | 1.64 | 1.74 | 1.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.46 | 1.64 | 1.74 | 1.61 | |
Free Cash Flow |
(10.65) | 1.24 | 24.71 | 29.14 | |
Working Capital |
166.87 | 195.78 | 213.21 | 196.41 | |
Capital Expenditures |
(0.63) | (0.64) | (0.25) | (0.19) | |
Net Current Asset Value |
140.37 | 174.59 | 191.37 | 174.05 | |
EV/EBIT |
51.47 | 11.22 | 13.34 | 16.88 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
65.02 | 14.81 | 15.66 | 19.18 | |
| Other line items | |||||
Average Receivables |
55.26 | 54.16 | 65.77 | 66.11 | |
Average Payables |
8.40 | 10.17 | 10.97 | 9.17 | |
Average Inventory |
22.91 | 25.15 | 24.57 | 25.38 | |
Average Assets |
286.05 | 289.55 | 303.28 | 281.44 | |
Average Common Equity |
216.31 | 222.86 | 224.83 | 209.98 |
Columns are period end dates